See All Slides - tctmd.com

Slides

Presentation TCT 2015

STEMI: Treatment Strategies, Drugs, and Devices

Presenter: Tayo A. Addo, Dharam J. Kumbhani

October 11, 2015

Presentation TCT 2015

USA Presents: Scaffold-Vessel Interactions: What the Interventionalist Should Know

Presenter: George D. Dangas, Eric Van Belle, Richard J. Rapoza

October 11, 2015

Presentation TCT 2015

Shades of Gray? Defining the Range of Patients Contraindicated for Anticoagulation

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Piera Capranzano

October 11, 2015

Presentation TCT 2015

The Mitral Valve Heart Team: How to Make This More Than a Concept

Presenter: Patrick T. O'Gara, Allan Schwartz, David L. Brown

October 11, 2015

Presentation TCT 2015

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Presenter: Stephen G. Ellis, John A. Ormiston, Philip M. Urban

October 11, 2015

Presentation TCT 2015

Predicting Periprocedure MI: Data From Grayscale and RF-IVUS, OCT, and NIRS

Presenter: Fernando Alfonso, Akiko Maehara, Evelyn S. Regar

October 11, 2015

Presentation TCT 2015

Which Patients for TAVR? Will Surgical Risk Stratification Remain the Dominant Strategy in the Future?

Presenter: Eberhard Grube, Michael J. Mack, John G. Webb

October 11, 2015

Presentation TCT 2015

Whats Controversial or Unsettled in the Guidelines?

Presenter: Patrick T. O'Gara, Allan Schwartz, Robert O. Bonow

October 11, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Presenter: Stephen G. Ellis, John A. Ormiston, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Presenter: Gary M. Ansel, Michael R. Jaff, Ravish Sachar

October 11, 2015

Advertisement

Slides

STEMI: Treatment Strategies, Drugs, and Devices

USA Presents: Scaffold-Vessel Interactions: What the Interventionalist Should Know

Shades of Gray? Defining the Range of Patients Contraindicated for Anticoagulation

The Mitral Valve Heart Team: How to Make This More Than a Concept

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Predicting Periprocedure MI: Data From Grayscale and RF-IVUS, OCT, and NIRS

Which Patients for TAVR? Will Surgical Risk Stratification Remain the Dominant Strategy in the Future?

Whats Controversial or Unsettled in the Guidelines?

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content